Anti-Corruption Compliance and Due Diligence

Hogan Lovells knows the FCPA and bribery and corruption laws around the world. We help you design intelligent and analytics-driven compliance programs that are practical and reduce your risk. We also help clients engaging in mergers and acquisitions to identify and mitigate potential exposure from past violations of applicable anti-corruption laws.

We have experience in the entire spectrum of anti-corruption compliance and transactional due diligence, from designing compliance programs, conducting risk-based diligence, performing effective internal investigations and fact-finding, to ensuring complete post-acquisition integration.

We offer pragmatic, business-savvy counsel. We appear regularly before the DOJ and SEC and are deeply conversant in their evolving expectations. Let our team help yours.

Key contacts

T. Clark Weymouth

Senior Counsel

T. Clark Weymouth

Senior Counsel

Washington, D.C.

Stephanie Yonekura

Partner

Stephanie Yonekura

Partner

Los Angeles

Peter S. Spivack

Partner

Peter S. Spivack

Partner

Washington, D.C.

Lillian S. Hardy

Partner

Lillian S. Hardy

Partner

Washington, D.C.

Meet the Anti-Corruption Compliance and Due Diligence team

Representative experience

Conducted a worldwide distributor compliance review for a leading pharmaceutical manufacturer as part of post-acquisition integration, following its largest acquisition ever.

Conducted a nine-country compliance review for one of the world's leading gold mining companies.

Advised a major automaker on the FCPA analysis and remedial actions related to facilitating payments made by a potential target to officials in India.

Advised a major Russian consumer product company on the potential FCPA exposure in connection with its financing practices.

Developed global anti-bribery corruption training to tech company with focus on the United States, UK, Brazil, India, and China. Provided in-person training to employees from the C-suite to on-the-ground salespeople.

Advised a publicly traded global pharmaceutical company on the anti-corruption due diligence and remedial actions related to clinical trials in several African countries.